FR20C1016I1 - - Google Patents

Info

Publication number
FR20C1016I1
FR20C1016I1 FR20C1016C FR20C1016I1 FR 20C1016 I1 FR20C1016 I1 FR 20C1016I1 FR 20C1016 C FR20C1016 C FR 20C1016C FR 20C1016 I1 FR20C1016 I1 FR 20C1016I1
Authority
FR
France
Prior art keywords
immunization
vaccines
viral particles
recombinant vsv
vsv viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
English (en)
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31188416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR20C1016(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR20C1016I1 publication Critical patent/FR20C1016I1/fr
Application granted granted Critical
Publication of FR20C1016I2 publication Critical patent/FR20C1016I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
    • C12N2760/14234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR20C1016C 2002-07-26 2020-05-06 Vaccins recombinants issu du virus de la stomatite vesiculaire dirige contre les fievres hemorragiques virales Active FR20C1016I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39855202P 2002-07-26 2002-07-26
PCT/CA2003/001125 WO2004011488A2 (en) 2002-07-26 2003-07-28 Recombinant vesicular stomatitis virus vaccines for viral hemorrhagic fevers

Publications (2)

Publication Number Publication Date
FR20C1016I1 true FR20C1016I1 (zh) 2020-06-12
FR20C1016I2 FR20C1016I2 (fr) 2022-04-01

Family

ID=31188416

Family Applications (1)

Application Number Title Priority Date Filing Date
FR20C1016C Active FR20C1016I2 (fr) 2002-07-26 2020-05-06 Vaccins recombinants issu du virus de la stomatite vesiculaire dirige contre les fievres hemorragiques virales

Country Status (9)

Country Link
US (1) US8012489B2 (zh)
EP (1) EP1527087B2 (zh)
AT (1) ATE455124T1 (zh)
AU (1) AU2003250680A1 (zh)
CA (1) CA2493142C (zh)
DE (1) DE60330966D1 (zh)
ES (1) ES2338416T5 (zh)
FR (1) FR20C1016I2 (zh)
WO (1) WO2004011488A2 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009116983A2 (en) * 2007-12-18 2009-09-24 Trustees Of Boston University Compositions and methods for treating ebola virus infection
JP5636284B2 (ja) * 2007-12-18 2014-12-03 トラスティーズ オブ ボストン ユニバーシティ フィロウイルスまたはアレナウイルス感染の暴露前または暴露後の治療法
CA2741523C (en) 2008-10-24 2022-06-21 Jonathan S. Towner Human ebola virus species and compositions and methods thereof
JP5675789B2 (ja) 2009-06-08 2015-02-25 ザ ユニバーシティー オブ ウェスタン オンタリオＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｗｅｓｔｅｒｎ Ｏｎｔａｒｉｏ 免疫接種のための発現ベクターとしての水疱性口内炎ウイルスの異なる複数の抗原型
US9402891B2 (en) * 2011-06-08 2016-08-02 Ohio State Innovation Foundation Norovirus immunogens and related materials and methods
US9474796B2 (en) 2012-08-14 2016-10-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Crimean-Congo hemorrhagic fever virus vaccine
US9795665B2 (en) 2012-08-14 2017-10-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Attenuated live vaccine for Crimean-Congo hemorrhagic fever virus and Erve virus
WO2015077714A1 (en) 2013-11-22 2015-05-28 Yale University Chimeric vsv virus compositions and methods of use thereof for treatment of cancer
WO2018111735A1 (en) * 2016-12-15 2018-06-21 Merck Sharp & Dohme Corp. A cell-based reporter assay for live virus vaccines
US20200276297A1 (en) * 2017-09-15 2020-09-03 Ohio State Innovation Foundation Vaccines and methods of making and using vaccines for prevention of respiratory syncytial virus (rsv) infections
US11274282B2 (en) 2019-05-15 2022-03-15 Board Of Regents, The University Of Texas System Vesicular stomatitis vectors encoding Crimean-Congo hemorrhagic fever antigen
MX2022013030A (es) 2020-04-17 2023-03-09 Regeneron Pharma Ensayos de deteccion para anticuerpos neutralizantes de coronavirus.
US20230149536A1 (en) 2020-04-17 2023-05-18 Vyriad, Inc. Compositions for treating and/or preventing coronavirus infections
WO2024159071A1 (en) 2023-01-27 2024-08-02 Regeneron Pharmaceuticals, Inc. Modified rhabdovirus glycoproteins and uses thereof
CN117925662B (zh) * 2023-12-19 2024-08-13 军事科学院军事医学研究院军事兽医研究所 一种重组水泡性口炎病毒以及埃博拉出血热感染动物模型的构建方法

Also Published As

Publication number Publication date
WO2004011488A2 (en) 2004-02-05
AU2003250680A1 (en) 2004-02-16
FR20C1016I2 (fr) 2022-04-01
ES2338416T3 (es) 2010-05-07
WO2004011488A3 (en) 2004-04-15
CA2493142C (en) 2013-11-12
EP1527087B1 (en) 2010-01-13
DE60330966D1 (de) 2010-03-04
WO2004011488A9 (en) 2004-06-03
US20060193872A1 (en) 2006-08-31
ES2338416T5 (es) 2013-11-20
US8012489B2 (en) 2011-09-06
EP1527087B2 (en) 2013-07-17
CA2493142A1 (en) 2004-02-05
AU2003250680A8 (en) 2004-02-16
ATE455124T1 (de) 2010-01-15
EP1527087A2 (en) 2005-05-04

Similar Documents

Publication Publication Date Title
FR20C1016I1 (zh)
IL210378A0 (en) Tumor associated antigen, peptides thereof, and use of same as ati-tumor vaccines
UA85536C2 (en) Viral antigens
IL212138A0 (en) Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
DK0757717T3 (da) Papillomavirusvacciner
SG158141A1 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
PT1673460E (pt) Vacinas recombinantes e suas utilizações
PL371007A1 (en) Macrocyclic peptides active against the hepatitis c virus
EP1622574A4 (en) EXPRESSION SYSTEMS OF RECOMBINANT PARAINFLUENZA VIRUSES AND VACCINES COMPRISING HETEROLOGOUS ANTIGENS DERIVED FROM METAPNEUMOVIRUS
WO2003103571A3 (en) VACCINES AGAINST FLAVIVIRUSES
TW200641126A (en) N protein mutants of porcine reproductive and respiratory syndrome virus
ZA200308589B (en) Recombinant fusion proteins and the trimers thereof.
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
EP1575601A4 (en) RECOMBINANT VACCINE VIRUSES EXPRESSING IL-15 AND METHODS OF USING THE SAME VIRUSES
IL173929A (en) Kahlalid F analogs and their pharmacy preparations
ATE386049T1 (de) Epstein-barr virus type b ctl epitopen
TW200636067A (en) Mutant porcine reproductive and respiratory syndrome virus
SG185137A1 (en) Biologically active peptides
AU2003293807A1 (en) Mhc class i restricted t-cell stimulating peptides from hepatitis b virus
AU2003246485A8 (en) Interactions of the epstein-barr virus protein ebna1, and uses thereof
GB0409559D0 (en) Polypeptide
AU2003240866A1 (en) Antibodies, peptides and vaccines against hiv-1 virus
AU2002321852A1 (en) Recombinant polypeptide for immunocastration and vaccine comprising the same
GB0213446D0 (en) Methods for making recombinant viruses and vaccines